-   $115.1 million   follow-on financing completed in February 2021 - First patient dosed in Phase 1 clinical trial with EYP-1901 in January 2021 -   $16.5 million monetization of ILUVIEN Royalty with $15 million applied to reduction in debt obligations in December 2020   - $15.7 million equity

WATERTOWN, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that management will present at two

WATERTOWN, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and

WATERTOWN, Mass. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of an underwritten

WATERTOWN, Mass. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten

WATERTOWN, Mass. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it intends to offer and sell

WATERTOWN, Mass. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the first patient has been

- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal  anti-VEGF treatment targeting wet age-related macular degeneration - - Anticipated Phase 1 clinical trial initiation in Q1 2021 - - Q4 2020 net product revenues are estimated to be $6.2 - $6.6

WATERTOWN, Mass. , Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics , a China -based ophthalmic pharmaceutical company

WATERTOWN, Mass. , Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders, today announced a royalty monetization

WATERTOWN, Mass. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it will effect a 1-for-10 reverse stock split at 5:00 p.m.

- No unexpected safety findings during the course of the study - -   On track to file an IND by end of year; Phase 1 clinical trial to commence in early 2021 - WATERTOWN, Mass. , Dec. 03, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to

WATERTOWN, Mass. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local

-   Second Phase 3 trial of YUTIQ   confirms 36-month   positive efficacy   results from the first Phase 3 trial - -   Study of DEXYCU vs. Prednisolone e ye d rops shows high patient preference for D EXYCU regimen with statistically better inflammation control, pain, visual acuity outcomes in D

WATERTOWN, Mass. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ® and DEXYCU® have been selected for

- Total revenues of $ 15.7 million and net product revenues of $ 5. 8 million - -   S equential quarterly increase in underlying customer demand of   over 12 0 % for DEXYCU ® and over 5% for YUTIQ®   - - EYP-1901, a potential six-month sustained delivery   intravitreal anti-VEGF treatment targeting

WATERTOWN, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020 .

WATERTOWN, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC (CRG).

- Q 3 20 20 net product revenues are estimated to be between $ 5.5   - $ 5.9   million, as   healthcare facilities began reopening from COVID-19 closures - - Sequential increase in underlying customer demand for both YUTIQ and DEXYCU from Q2 2020 WATERTOWN, Mass. , Oct.

WATERTOWN, Mass. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker , President and Chief Executive Officer, will present in two